ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Neuronetics Inc

Neuronetics Inc (STIM)

5.57
0.51
( 10.08% )
업데이트: 03:06:23

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
5.57
매수가
5.57
매도가
5.58
거래량
2,137,078
5.07 일간 변동폭 5.92
0.52 52주 범위 5.92
market_cap
전일 종가
5.06
개장가
5.47
최근 거래 시간
100
@
5.57
마지막 거래 시간
03:06:23
재정 규모
US$ 11,854,061
VWAP
5.5469
평균 볼륨(3m)
1,347,801
발행 주식
30,347,504
배당수익률
-
주가수익률
-5.46
주당순이익(EPS)
-0.99
매출
71.35M
순이익
-30.19M

Neuronetics Inc 정보

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-sy... Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. 더 보기

섹터
Surgical,med Instr,apparatus
산업
Surgical,med Instr,apparatus
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Neuronetics Inc is listed in the Surgical,med Instr,apparatus sector of the 나스닥 with ticker STIM. The last closing price for Neuronetics was US$5.06. Over the last year, Neuronetics shares have traded in a share price range of US$ 0.52 to US$ 5.92.

Neuronetics currently has 30,347,504 shares in issue. The market capitalisation of Neuronetics is US$153.56 million. Neuronetics has a price to earnings ratio (PE ratio) of -5.46.

Neuronetics (STIM) 옵션 플로우 요약

전체 흐름

강세

순 프리미엄

28k

Calls / Puts

100.00%

매수 / 매도

100.00%

OTM / ITM

0.00%

Sweeps 비율

0.00%

STIM 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
11.1626.30385487534.415.924.0820117324.75596944CS
42.1160.98265895953.465.922.822322864.16970573CS
124.435390.7488986781.1355.921.0513478013.45309395CS
264.76587.6543209880.815.920.528354562.70481435CS
522.5785.666666666735.920.525402202.52312775CS
1562.581.43322475573.076.930.523439222.98345778CS
2602.89107.8358208962.6822.430.523903765.07511511CS

STIM - Frequently Asked Questions (FAQ)

What is the current Neuronetics share price?
The current share price of Neuronetics is US$ 5.57
How many Neuronetics shares are in issue?
Neuronetics has 30,347,504 shares in issue
What is the market cap of Neuronetics?
The market capitalisation of Neuronetics is USD 153.56M
What is the 1 year trading range for Neuronetics share price?
Neuronetics has traded in the range of US$ 0.52 to US$ 5.92 during the past year
What is the PE ratio of Neuronetics?
The price to earnings ratio of Neuronetics is -5.46
What is the cash to sales ratio of Neuronetics?
The cash to sales ratio of Neuronetics is 2.31
What is the reporting currency for Neuronetics?
Neuronetics reports financial results in USD
What is the latest annual turnover for Neuronetics?
The latest annual turnover of Neuronetics is USD 71.35M
What is the latest annual profit for Neuronetics?
The latest annual profit of Neuronetics is USD -30.19M
What is the registered address of Neuronetics?
The registered address for Neuronetics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Neuronetics website address?
The website address for Neuronetics is www.neurostar.com
Which industry sector does Neuronetics operate in?
Neuronetics operates in the SURGICAL,MED INSTR,APPARATUS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
GVVisionary Holdings Inc
US$ 2.6606
(106.25%)
136.75M
CMRXChimerix Inc
US$ 8.435
(70.06%)
110.33M
ARBBARB IOT Group Ltd
US$ 0.82
(57.69%)
75.73M
CDXCChromaDex Corporation
US$ 8.81
(57.32%)
15.54M
PRTSCarParts com Inc
US$ 1.245
(41.28%)
7.21M
CUTRCutera Inc
US$ 0.145
(-53.88%)
11.25M
LBGJLi Bang International Corporation Inc
US$ 1.36
(-32.00%)
220.72k
XCURExicure Inc
US$ 9.9339
(-30.43%)
112.94k
STBXStarBox Group Holdings Ltd
US$ 0.35
(-28.82%)
1.26M
CLEUChina Liberal Education Holdings Ltd
US$ 2.83
(-21.17%)
260.62k
NVDANVIDIA Corporation
US$ 117.655
(1.44%)
163.39M
ADTXAditxt Inc
US$ 0.0603
(21.08%)
137.36M
GVVisionary Holdings Inc
US$ 2.6606
(106.25%)
136.75M
CMRXChimerix Inc
US$ 8.4375
(70.11%)
110.33M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 11.745
(1.86%)
80.44M

STIM Discussion

게시물 보기
TrendTrade2016 TrendTrade2016 4 시간 전
STIM..BLOWING UP...BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 4 시간 전
STIM GAPPA
👍️ 1
glenn1919 glenn1919 7 시간 전
STIM.......................................................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 일 전
STIM THERES THE BREAK OUT...MARKET LOVES THIS PLAY
👍️0
glenn1919 glenn1919 1 일 전
STIM....................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 주 전
STIM HERES THE BREAK OUT...MONSTER BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 주 전
STIM ULATING...BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 주 전
STIM ONE MORE BIG PUSH COMING
👍️0
glenn1919 glenn1919 2 주 전
STIM................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 주 전
STIM.........................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 주 전
STIM...FULL OT WEEKLY BREAK OUT...BIO BEAST OFF OFFERING
👍️ 1
TrendTrade2016 TrendTrade2016 3 주 전
STIM MASSIVE BREAK OUT COMING OFF AN OFFERING....MONSTER BIO
👍️0
glenn1919 glenn1919 3 주 전
STIM.................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 주 전
STIM............................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
STIM BEAST IS BEASTING THROUGH BEASTVILLE
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
STIM WEEKLY PUSH....IS STIMULATING!!!
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
STIM HERE W EGO NOW
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
STIM....GETTING MORE STIMULATING
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
STIM....ULATING
👍️0
glenn1919 glenn1919 1 월 전
STIM..................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
STIM...ON THE CUSP OF WEEKLY BREAKOUT
👍️0
glenn1919 glenn1919 1 월 전
STIM..............................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
STIM.......................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
STIM WHAT A BEAUTIFUL DAYTRADE
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
STIM MONSTER
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
STIM ON THE MOVE
👍️0
glenn1919 glenn1919 2 월 전
STIM........................................https://stockcharts.com/h-sc/ui?s=STIM&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 월 전
STIM under $3
👍️0
Dubster watching Dubster watching 10 월 전
Going to do it again!
👍️0
Dubster watching Dubster watching 10 월 전
Got 6% 2 hours
👍️0
Dubster watching Dubster watching 10 월 전
Momentum play!
👍️0
Monksdream Monksdream 1 년 전
STIM 10Q due March 5
👍️0
Monksdream Monksdream 1 년 전
STIM new 52 week low
👍️0
Monksdream Monksdream 1 년 전
STIM new 52 week low
👍️0
AJ Freely AJ Freely 2 년 전
$STIM - 👆Up 6.8% Pre-Market/ Current Price $2.06
Reports Record Q2 '23 Financial & Operating Results
👉Q2 '23 revenue of $17.6m, an increase of 8% over the Q2 '22
👉U.S. treatment session revenue increased 9% over the Q2 of '22
👉Shipped 54 NeuroStar systems
👍️0
luckydude777 luckydude777 3 년 전
Slowly moving UP. VERY INTERESTED in their technology. In time, we may be looking at a very LUCRATIVE company here.

We'll see ...
👍️0
luckydude777 luckydude777 3 년 전
Wow - after hours filled the gap in ONE day. Very interesting ...
👍️0
luckydude777 luckydude777 3 년 전
How big of a deal do you think today's news IS?
👍️0
subslover subslover 3 년 전
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
July 19 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including drug-resistant depression and obsessive-compulsive disorder (OCD), announced clearance from the U.S. Food and Drug Administration (FDA) for a new indication for its transcranial magnetic stimulation (TMS) system – NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression.
“Today, we celebrate a big win for NeuroStar patients and providers,” said Keith J. Sullivan, President and CEO of Neuronetics Inc. “Many people suffering from MDD also experience anxiety symptoms, and these patients with anxious depression are more likely to be severely depressed and to have more thoughts of suicide. This new indication means providers can now describe to MDD patients the benefit of NeuroStar for improving their anxiety symptoms.”

NeuroStar is the leader in patient-focused TMS therapy having treated over 134,000 patients who completed more than 4.8 million treatment sessions. The FDA accepted Neuronetics’ use of real-world data analyzed from NeuroStar’s proprietary TrakStar® platform in granting clearance for this new indication. The TrakStar database contains digital data from patients treated with NeuroStar at over 1,000 centers. Real-world data from TrakStar is particularly valuable because it provides a large sample from a diverse patient group being treated in a clinical practice setting.

“We would like to acknowledge the contributions of healthcare providers across the country who have partnered with us to help build the world’s largest database of depression outcomes,” said Cory Anderson, VP R&D and Clinical. “Not only do we have MDD outcomes, but we also receive data on anxiety outcomes from patients with anxious depression, and these real-world results in anxious depression were an important piece of the FDA clearance.”

The TrakStar results from 664 anxious depression patients demonstrated that 65.5% achieved a clinically meaningful response which exceeded the pre-established overall study success criteria of a minimum 50% response rate (p<0.0001) and indicated a large treatment effect size of 1.4.

“A clinical presentation of anxiety symptoms in patients with MDD is typically more complex to successfully treat with currently available medications,” said Melissa Fickey, MD, founder of Embracing Life Wellness Center. “NeuroStar has presented a robust data set from over 1,300 patients showing safety and efficacy in relieving both depression and anxiety symptoms in patients with anxious depression.”

DASH, TouchStar™, and standard MDD protocols offered by NeuroStar are all now indicated to treat depression with comorbid anxiety. This clearance closely follows after NeuroStar’s announcement of an obsessive compulsive disorder (OCD) indication, which received FDA clearance in May of this year. For more information about NeuroStar Advanced Therapy for Mental Health, please visit neurostar.com

About Anxious Depression
Major depressive disorder (MDD) is a common and serious psychiatric diagnosis among adults with an estimated prevalence of 13.9M patients under treatment in the United States. Anxiety symptoms are a common co-morbidity in patients with MDD, commonly called anxious depression, with an estimated prevalence of more than 50% of MDD patients. The NeuroStar Advanced Therapy System is now indicated for treating anxiety symptoms for those who may exhibit comorbid anxiety and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decre
👍️0
urge2surge urge2surge 4 년 전
Guess we got a dog pile here..
👍️0
oxnous oxnous 4 년 전
UGLY day


👍️0
urge2surge urge2surge 4 년 전
Thank you I'll take a look. Yes it works. If they announce trials on Alzheimer's, who knows where this goes. As it is this is a solid growth company. I was surprised at the secondary offering in light of their revenues.
As for BWAY, the only negative off the cuff is that it is an Israeli company. Tend to be big sink holes...
👍️0
EarthBard EarthBard 4 년 전
Brains at (BWAY) is the only other company I know.

My son is an rTMS tech and tells me flat out that it works.

EB
👍️0
urge2surge urge2surge 4 년 전
This is a major winning technology an stock, and the board is dead??????
👍️0
urge2surge urge2surge 4 년 전
Looking at a solid and easy 100 dollar stock here. The treatments work!!!!
👍️0
urge2surge urge2surge 4 년 전
Are their any other public companies in this sector?
Thanks in advance
👍️0
TFMG TFMG 5 년 전
$STIM | #Neuronetics Inc +60% Potential Upside


Neuronetics , Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS , a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Average Analysts Recommendation: BUY
Average Target Price: $5.75




👍️0
wesley_ wesley_ 5 년 전
$4.64
👍️0
wesley_ wesley_ 5 년 전
$3.96
👍️0
wesley_ wesley_ 5 년 전
$3.85
👍️0